AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
GOOGL   1,241.20 (-0.25%)
AMZN   1,765.73 (-1.12%)
CGC   21.15 (+3.93%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
GOOGL   1,241.20 (-0.25%)
AMZN   1,765.73 (-1.12%)
CGC   21.15 (+3.93%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
Log in

Catalyst Biosciences Stock Price, News & Analysis (NASDAQ:CBIO)

$5.29
-0.13 (-2.40 %)
(As of 10/22/2019 04:00 PM ET)
Today's Range
$5.22
Now: $5.29
$5.65
50-Day Range
$4.81
MA: $5.73
$6.58
52-Week Range
$4.52
Now: $5.29
$11.44
Volume90,918 shs
Average Volume189,654 shs
Market Capitalization$63.56 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-871-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$10.04 per share

Profitability

Net Income$-30,060,000.00

Miscellaneous

Employees21
Market Cap$63.56 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.


Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences shares reverse split on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences Inc (NASDAQ:CBIO) announced its quarterly earnings data on Thursday, August, 1st. The biopharmaceutical company reported ($1.15) EPS for the quarter, beating the Zacks' consensus estimate of ($1.16) by $0.01. View Catalyst Biosciences' Earnings History.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Catalyst Biosciences.

What price target have analysts set for CBIO?

3 brokerages have issued twelve-month price targets for Catalyst Biosciences' stock. Their forecasts range from $24.00 to $25.00. On average, they anticipate Catalyst Biosciences' stock price to reach $24.33 in the next year. This suggests a possible upside of 360.0% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.

What is the consensus analysts' recommendation for Catalyst Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.

Has Catalyst Biosciences been receiving favorable news coverage?

Media headlines about CBIO stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalyst Biosciences earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Catalyst Biosciences.

Are investors shorting Catalyst Biosciences?

Catalyst Biosciences saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 285,600 shares, a decrease of 11.3% from the August 30th total of 322,000 shares. Based on an average daily volume of 134,500 shares, the days-to-cover ratio is currently 2.1 days. Approximately 2.6% of the shares of the stock are sold short. View Catalyst Biosciences' Current Options Chain.

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the folowing people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 59)
  • Mr. Fletcher Payne, Chief Financial Officer (Age 56)
  • Dr. Howard Levy, Chief Medical Officer (Age 65)
  • Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.17%). Company insiders that own Catalyst Biosciences stock include Howard Levy, James E Flynn and John P Richard. View Institutional Ownership Trends for Catalyst Biosciences.

Which major investors are buying Catalyst Biosciences stock?

CBIO stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Catalyst Biosciences.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $5.29.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $63.56 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-30,060,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.View Additional Information About Catalyst Biosciences.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is http://www.catalystbiosciences.com/.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]


MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel